TXG earnings call for the period ending December 31, 2019.
News & Analysis: 10x Genomics Inc
The company scored an important win in a patent dispute.
TXG earnings call for the period ending September 30, 2019.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.
The recent crop of new stocks runs the gamut from R&D stage biotech to a Fortune 500 spin-off with billions in revenue.